deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03125577

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies

Sponsor: Shenzhen Geno-Immune Medical Institute

Conditions B-cell Malignancies
Interventions 4SCAR19 and 4SCAR123 4SCAR19 and 4SCAR20 4SCAR19 and 4SCAR22 4SCAR19 and 4SCAR30 4SCAR19 and 4SCAR38 4SCAR19 and 4SCAR70
Updated 10 times since 2017 Last updated: Sep 4, 2025 Started: Aug 1, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates B-cell Malignancies and is currently actively recruiting participants. Shenzhen Geno-Immune Medical Institute leads this study, which shows 10 recorded versions since 2025 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshotRecruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotRecruiting~Sep 2018 – ~Oct 2019 · 13 months · monthly snapshotRecruiting~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotRecruiting~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshotUnknown~Oct 2025 – present · 9 months · monthly snapshotRecruiting

Change History

10 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1/PHASE2

    Status: Unknown → Recruiting

  2. Sep 2024 — Oct 2025 [monthly]

    Unknown PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  5. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Oct 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2018 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  4. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shenzhen Geno-Immune Medical Institute
Data source: Shenzhen Geno-Immune Medical Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations